Added to YB: 2026-05-12
Pitch date: 2026-05-10
ANNX [neutral]
Annexon, Inc.
-1.73%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Market Cap
$932.3M
Pitch Price
$5.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.73
P/E
-4.78
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Q1 Earnings Wire May 8, 2026 PM Drop - Annexon, Inc.
ANNX (earnings): Q1 net loss $44.1M, R&D cut to $35.8M from $48.2M. $225M cash, runway into 2H 2027. Vonaprument ARCHER II Ph3 GA topline Q4 2026 (659 pts, primary: 15-letter BCVA loss @ month 15), only GA w/ EMA PRIME+FDA FastTrack. Tanruprubart EU MAA for GBS, BLA w/ FORWARD data 2026. ANX1502 oral C1 inhib POC 2026. 3 catalysts.
Read full article (1 min)